Bayer HealthCare
Pharmaceuticals
-
Thursday - November 29, 2012
European Innovative Medicines Initiative (IMI):
Bayer supports pharmaceutical research in Europe
Bayer HealthCare and Leiden University coordinate consortium to optimize binding kinetics for drug candidates » more
-
Wednesday - November 28, 2012
Not intended for U.S. and UK Media - Hemophilia solutions:
Bayer completes recruitment of first cohort for novel recombinant factor VIIa (rFVIIa) protein Phase II/III study
Investigational new treatment for Hemophilia A and Hemophilia B patients who have developed neutralizing antibodies » more
-
Tuesday - November 27, 2012
Not intended for U.S. and UK Media
Bayer receives approval for EYLEA® in Europe for the Treatment of Wet Age-Related Macular Degeneration
New treatment allows dosing every other month following three initial monthly injections in wet AMD patients » more
-
Tuesday - November 20, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism (PE) and the Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE in the EU
Blood clots obstructing blood flow in deep veins or in the lungs kill more than 2,300 people every day worldwide and urgent action is essential to save lives / Rivaroxaban works as fast as injectable enoxaparin, providing efficacy when needed for as long as needed / Rivaroxaban offers the only oral single-drug solution for the treatment of PE and long-term prevention of DVT and PE, without the need for injections or monitoring / Rivaroxaban is approved to protect patients from blood clots across more venous and arterial thromboembolic diseases than any other novel oral anticoagulant » more
-
Tuesday - November 13, 2012
Not intended for U.S. and UK Media
Landmark Phase III Study of Bayer’s Xarelto® (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery Disease
20,000-patient study will be conducted in collaboration with Population Health Research Institute / Composite of cardiovascular death, myocardial infarction and stroke as primary efficacy endpoint / Rivaroxaban is the first novel oral anticoagulant under assessment in this high risk patient population » more
-
Friday - November 2, 2012
Not intended for U.S. and UK Media
U.S. FDA Approves Xarelto® (Rivaroxaban) to Treat Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) as well as to Reduce the Risk of Recurrent Events
Rivaroxaban is the only oral single-drug solution proven effective for the treatment of DVT and PE » more
-
Friday - November 2, 2012
Not intended for U.S. and UK Media
Bayer HealthCare strengthens position in Russia
Bayer enters strategic partnership to locally produce pharmaceuticals in Russia / Partnership will increase access of Russian patients to Bayer medicines » more
-
Monday - October 29, 2012
Not Intended for U.S. and U.K. Media
Bayer’s Stivarga® (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors » more
-
Friday - October 26, 2012
Not intended for U.S. and UK Media - American Heart Association (AHA) Scientific Sessions 2012:
Latest Xarelto® (Rivaroxaban) Data to be Presented at AHA 2012
Multiple sub-analyses to be presented from the important Phase III ROCKET AF Study in patients with non-valvular Atrial Fibrillation (AF) and heart failure or diabetes / Additional Phase III ATLAS ACS 2-TIMI 51 data analyses on rivaroxaban in secondary ACS prevention also to be presented » more
-
Thursday - October 25, 2012
Not intended for U.S. and UK media
Bayer HealthCare and Qiagen Collaborate to Develop Companion Diagnostic Tests in Oncology » more
-
Thursday - October 25, 2012
Not intended for U.S. and UK Media - 68th Meeting of American Society for Reproductive Medicine in San Diego:
Bayer HealthCare’s new hormone-releasing intrauterine systems proven effective and well tolerated in Phase III study » more
-
Tuesday - October 23, 2012
Not intended for U.S. and UK Media
Bayer’s Riociguat First Drug to Demonstrate Efficacy in Patients with Chronic Thromboembolic Pulmonary Hypertension
Phase III CHEST-1 study met its primary endpoint, demonstrating a statistically significant improvement in the six-minute walk test (6MWT) in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH) treated with riociguat / Riociguat was well tolerated with a good safety profile » more
-
Tuesday - October 23, 2012
Industrial research at the highest scientific level:
Otto Bayer Medals for Excellence in Research
Three Bayer research teams have been honored for excellent innovations / Budget for research and development of EUR 3 billion in 2012 » more
-
Monday - October 22, 2012
Not intended for U.S. and UK Media
Bayer’s Riociguat Meets Primary Endpoint in Pivotal Phase III Study in Patients with Pulmonary Arterial Hypertension
Riociguat demonstrates a statistically significant improvement in the six-minute walk test (6MWT) in both treatment-naïve patients and in patients pre-treated with endothelin receptor antagonists (ERAs) or non-intravenous (non-iv) prostanoid monotherapy / Riociguat was well tolerated with a good safety profile » more
-
Friday - October 19, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Recommended for EU Approval for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
Rivaroxaban offers the first oral single-drug solution for the treatment of PE and long-term prevention of DVT and PE / Decision of European Commission on approval expected before year-end » more
-
Wednesday - October 17, 2012
Not intended for U.S. and UK media
Bayer to present data on novel pulmonary hypertension drug, Riociguat, at CHEST 2012 congress in Atlanta
First data from Phase III trials for riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) in late-breaking news presentation » more
-
Tuesday - October 9, 2012
Not intended for U.S. and UK Media
European Commission gives green light to Bayer HealthCare’s Flexyess®
Flexyess is the first combined oral contraceptive with a flexible extended dosing regimen offering women "personal period planning" » more
-
Monday - October 1, 2012
Not intended for U.S. and UK Media
Bayer HealthCare enters into multi-target alliance to fight endometriosis » more
-
Friday - September 28, 2012
Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan » more
-
Thursday - September 27, 2012
Not Intended for U.S. and U.K. Media
Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Stivarga shown in a pivotal Phase III trial to extend overall survival in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after previous treatments » more
Copyright @ Bayer AG
Search
Links
Publications
research – The Bayer Scientific Magazine
Stockholders' Newsletter
Annual Report
Sustainable Development Report
Publications Overview
Newsletter
Events
Download Center - Selection